Figure 1. Serum OPG levels during neoadjuvant therapy.

Using the single-parameter immunoassay, OPG was measured in serum sampled from patients at baseline (n = 74), post-NACT (n = 64), post-CRT (n = 61), and at evaluation of the neoadjuvant treatment (n = 57). For each sample group, where mean value is indicated by a line, distribution of values was different from baseline (* P < 0.01, ** P < 0.0001; calculated by unpaired one-way analysis of variance).